Royalty Pharma (RPRXN) Ratios
Royalty Pharma Ratios
MX:RPRXN's free cash flow for Q2 2026 was $686.15M. For the 2026 fiscal year, MX:RPRXN's free cash flow was increased by $0.00 and operating cash flow was $686.15M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.97 | 1.44 | 7.90 | 2.19 | 16.81 |
| Quick Ratio | 0.97 | 1.44 | 7.90 | 2.19 | 16.81 |
| Cash Ratio | 0.97 | 0.74 | 2.96 | 1.47 | 9.00 |
| Solvency Ratio | 0.08 | 0.11 | 0.18 | 0.01 | 0.09 |
| Operating Cash Flow Ratio | 3.91 | 2.21 | 18.51 | 1.84 | 11.78 |
| Short-Term Operating Cash Flow Coverage | 6.55 | 2.78 | 0.00 | 2.15 | 0.00 |
| Net Current Asset Value | $ -9.29B | $ -6.08B | $ -5.02B | $ -4.73B | $ -4.39B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.46 | 0.42 | 0.37 | 0.42 | 0.41 |
| Debt-to-Equity Ratio | 1.38 | 1.10 | 0.94 | 1.26 | 1.23 |
| Debt-to-Capital Ratio | 0.58 | 0.52 | 0.48 | 0.56 | 0.55 |
| Long-Term Debt-to-Capital Ratio | 0.57 | 0.49 | 0.48 | 0.52 | 0.55 |
| Financial Leverage Ratio | 3.03 | 2.62 | 2.51 | 2.99 | 3.03 |
| Debt Service Coverage Ratio | 2.38 | 1.27 | 10.08 | 0.36 | 8.61 |
| Interest Coverage Ratio | 5.07 | 5.73 | 7.97 | 1.63 | 8.61 |
| Debt to Market Cap | 0.54 | 0.67 | 0.49 | 0.41 | 0.43 |
| Interest Debt Per Share | 21.44 | 17.57 | 14.13 | 16.68 | 17.51 |
| Net Debt to EBITDA | 5.09 | 4.29 | 3.00 | 12.76 | 3.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 68.62% | 68.76% | 80.15% | 18.69% | 61.47% |
| EBITDA Margin | 68.78% | 68.76% | 80.15% | 18.94% | 62.47% |
| Operating Profit Margin | 65.58% | 57.10% | 63.37% | 13.73% | 62.49% |
| Pretax Profit Margin | 55.68% | 58.79% | 72.20% | 10.28% | 54.21% |
| Net Profit Margin | 32.42% | 37.95% | 48.20% | 1.91% | 27.07% |
| Continuous Operations Profit Margin | 55.68% | 58.79% | 72.20% | 10.28% | 54.21% |
| Net Income Per EBT | 58.22% | 64.55% | 66.75% | 18.62% | 49.93% |
| EBT Per EBIT | 84.91% | 102.97% | 113.94% | 74.92% | 86.75% |
| Return on Assets (ROA) | 3.93% | 4.71% | 6.93% | 0.25% | 3.54% |
| Return on Equity (ROE) | 11.90% | 12.37% | 17.39% | 0.76% | 10.73% |
| Return on Capital Employed (ROCE) | 8.21% | 7.62% | 9.20% | 1.96% | 8.25% |
| Return on Invested Capital (ROIC) | 8.95% | 7.19% | 9.20% | 1.84% | 8.25% |
| Return on Tangible Assets | 4.12% | 27.75% | 6.93% | 0.25% | 3.54% |
| Earnings Yield | 4.62% | 7.55% | 9.03% | 0.25% | 3.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.69 | 83.97 | 105.09 | 61.13 | 33.52 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.12 | 0.12 | 0.14 | 0.13 | 0.13 |
| Working Capital Turnover Ratio | 8.95 | 2.73 | 1.88 | 1.09 | 0.90 |
| Cash Conversion Cycle | 135.63 | 4.35 | 3.47 | 5.97 | 10.89 |
| Days of Sales Outstanding | 135.63 | 4.35 | 3.47 | 5.97 | 10.89 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 135.63 | 4.35 | 3.47 | 5.97 | 10.89 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.76 | 6.21 | 6.68 | 4.90 | 4.86 |
| Free Cash Flow Per Share | 5.76 | 6.21 | 6.68 | 4.90 | 4.86 |
| Dividend Paid and CapEx Coverage Ratio | 6.58 | 7.36 | 8.34 | 6.43 | 7.07 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.28 | 0.36 | 0.49 | 0.30 | 0.28 |
| Operating Cash Flow to Sales Ratio | 1.05 | 1.22 | 1.27 | 0.96 | 0.88 |
| Free Cash Flow Yield | 14.92% | 24.34% | 23.76% | 12.39% | 12.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.58 | 13.29 | 11.08 | 404.10 | 26.67 |
| Price-to-Sales (P/S) Ratio | 7.02 | 5.03 | 5.34 | 7.74 | 7.22 |
| Price-to-Book (P/B) Ratio | 2.58 | 1.64 | 1.93 | 3.08 | 2.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.70 | 4.11 | 4.21 | 8.07 | 8.19 |
| Price-to-Operating Cash Flow Ratio | 6.70 | 4.11 | 4.21 | 8.07 | 8.19 |
| Price-to-Earnings Growth (PEG) Ratio | 0.78 | -0.30 | 0.00 | -4.32 | -0.63 |
| Enterprise Value Multiple | 15.30 | 11.60 | 9.66 | 53.61 | 15.44 |
| Enterprise Value | 25.02B | 18.06B | 18.23B | 22.71B | 22.08B |
| EV to EBITDA | 15.30 | 11.60 | 9.66 | 53.61 | 15.44 |
| EV to Sales | 10.52 | 7.98 | 7.74 | 10.15 | 9.65 |
| EV to Free Cash Flow | 10.05 | 6.52 | 6.10 | 10.59 | 10.95 |
| EV to Operating Cash Flow | 10.05 | 6.52 | 6.10 | 10.59 | 10.95 |
| Tangible Book Value Per Share | 20.35 | -10.73 | 22.53 | 21.75 | 24.69 |
| Shareholders’ Equity Per Share | 15.00 | 15.58 | 14.58 | 12.85 | 13.93 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 5.51 | 5.08 | 5.26 | 5.11 | 5.52 |
| Net Income Per Share | 1.79 | 1.93 | 2.54 | 0.10 | 1.49 |
| Tax Burden | 0.58 | 0.65 | 0.67 | 0.19 | 0.50 |
| Interest Burden | 0.81 | 0.86 | 0.90 | 0.55 | 0.88 |
| Research & Development to Revenue | 0.19 | 0.00 | 0.02 | 0.08 | 0.09 |
| SG&A to Revenue | 0.24 | 0.10 | 0.11 | 0.10 | 0.08 |
| Stock-Based Compensation to Revenue | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.88 | 2.08 | 1.76 | 9.32 | 1.63 |
Currency in USD
